Navigation Links
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,,Rheumatoid Arthritis and Lymphoma

very well tolerated in the first dose group. To expedite patient recruitment, Rigel has added additional clinical sites that have significant experience in RA clinical trials. Rigel expects to receive results from the completed clinical trial in the second half of 2007.

Rigel today announced the enrollment of patients in a multi-center, Phase 2 clinical trial to evaluate the safety and efficacy of R788 for the treatment of patients with B-cell lymphoma. Approximately 80% of patients with non- Hodgkin's lymphoma have the B-cell variety, which is characterized by an over- expression of B-cell receptors and the proliferation of B-cells. Research has shown that R788 effectively interrupts the growth of B-cells and signaling proteins that contribute to the survival of these tumors.

The open label clinical trial is expected to enroll a total of approximately 60 patients at 10 major cancer treatment centers in the U.S. and will focus on refractory diffuse large, follicular and mantle B-cell lymphomas. The primary efficacy endpoint will be overall response rate according to standard criteria. Secondary efficacy, safety and pharmacodynamic endpoints, as well as the role of syk activation in predicting responses, will also be measured. Depending on enrollment, results of the clinical trial are expected in 2008.

R788 is a novel, oral syk kinase inhibitor that blocks the activation of mast cells, macrophages and B-cells that promote swelling, inflammatory responses and tissue damage. These activities derive from syk kinase's pivotal role in mediating immunoglobulin signaling inside cells. It is currently being evaluated in two Phase 2 studies with respect to RA and ITP, and enrollment in an additional Phase 2 clinical trial in B-cell lymphoma has commenced. Phase 1 trial results demonstrated that R788 was well tolerated and showed good pharmaceutical properties when administered both alone and, with respect to the treatment of patients with RA, in combinat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
(Date:11/26/2014)... -- According to the new research ... Battery, Pneumatic), by Product (Drill, Saw, Stapler, Reamer, ... (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global Forecasts ... Instruments Market is estimated to be worth around ... expected to grow at a moderate CAGR during ...
(Date:11/26/2014)... , Nov. 25, 2014  Medtronic,s ... has been widely discussed in the media ... also creating a stronger leading player in one ... Kalorama Information.  The healthcare market research firm said ... will feature a diverse set of solutions spanning ...
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3
... 2011 UCB, a leading biopharmaceutical company at the forefront ... College of Gastroenterology (ACG) meeting in Washington, D.C. by reinforcing ... disease. At this year,s ACG meeting, a large body of ... in treatment of moderate to severe Crohn,s disease. ...
... Natrix Separations, Inc. announced today new members of its leadership ... Officer and Molly S. McGlaughlin as Vice President of Business ... of Directors since mid-2010, and will continue to hold a ... C. Howie Honeyman, Ph.D. will continue as Senior Vice ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 2UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 3Natrix Separations Introduces New Leadership Team 2Natrix Separations Introduces New Leadership Team 3
(Date:11/27/2014)... New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated litigation ... LLP reports. , Documents recently updated in ... records included in the state proceeding, all of ... bipolar disorder and other psychiatric conditions. Many of ...
(Date:11/27/2014)... Nov. 26, 2014 (HealthDay News) -- Most babies and ... cold, the U.S. Food and Drug Administration says. ... given to children younger than 2 because they could ... warned. American adults average about three colds a ... get a cold, parents might want to give them ...
(Date:11/27/2014)... Thanksgiving meals can pose a challenge for people who ... Many traditional Thanksgiving dishes -- such as turkey, ... but "when it comes to pies, stuffing, gravy, etc., ... Safta, director of the Gluten and Allergic Digestive Disorders ... Carolina, said in a center news release. "For ...
(Date:11/27/2014)... The founders of VIM & VIGR, a ... functioning compression socks, are proud to announce the debut of ... Gradient Pressure (TM) knitting technology that is designed to increase ... commitment to adding flair and style to a product that ... the eye of a writer at The New York ...
(Date:11/27/2014)... 2014 Now that Thanksgiving is finally ... launched, Emassagechair.com has announced its eagerly awaited, ... , Negotiating on behalf of their customers, and ... brands, Emassagechair.com has generated significant buzz in the industry ... discounts yet. , Shoppers are excited for significant savings ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4
... N.C., July 29 DiaLog, Inc., a ... joint agreement with DeliverMed,Holdings, LLC, an Illinois-based, ... the DiaLog System, promotes compliance,and adherence to ... and their,physicians better manage their disease. DeliverMed ...
... of people world-wide who have contracted a highly resistant ... new drug to treat the infection. , Research ... National Centre in HIV Epidemiology and Clinical Research (NCHECR) ... responded to traditional treatments have had good results from ...
... researchers note risk dissipates quickly once smoking spouse quits , , ... to smokers run a significantly higher risk for experiencing a ... ex-smokers married to men and women who still smoke carry ... former smokers do not appear to bear any higher risk ...
... ASHEVILLE, N.C., July 29 DoctorDirectory.com, ... DAVA Pharmaceuticals, Inc. to,co-market VoSpire ER(R) ... virtual marketing solution. IncreaseRx utilizes,web-based educational ... of thousands of,interested prescribers with targeted ...
... The,Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading ... will report,results for its second quarter 2008 ended June ... close., A conference call to review the results ... August 12, 2008 and will be hosted by Adam ...
... of Patients in National Survey Showed Reduction in Fall ... Strides,the pioneering home balance therapy program from Gentiva Health ... pain and,increasing sensation for thousands of older Americans, according ... released today by the Company., The year-long survey ...
Cached Medicine News:Health News:DiaLog Signs Agreement with DeliverMed to Improve Diabetic Patient Management 2Health News:New therapy for HIV treatment 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 3Health News:DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc. 2Health News:IPC The Hospitalist Company, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 2Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 3Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 4Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 5
Modular hip abduction system designed to provide superior fit, adjustability and functionality for optimum patient stability, comfort and compliance...
... Harness™ A Pavlik-type harness with greatly ... treatment of congenital hip dysplasia. Color-coded ... and antislip foot pieces.,Color-coded anterior straps ... can be made while the child ...
... in walker design in years. A real step forward! ... surfaces of the foot rest on adaptive areas of ... strike. The footbed in the sole conforms to the ... stability. , ,No leg length discrepancy; Heel height ...
... This low cost walker features a ... innersole. The low profile design minimizes leg ... with D-rings makes strapping quick and easy. ... to accomodate swollen ankles and extra bandaging. ...
Medicine Products: